263 related articles for article (PubMed ID: 32043781)
21. TERT promoter mutations in melanoma survival.
Nagore E; Heidenreich B; Rachakonda S; Garcia-Casado Z; Requena C; Soriano V; Frank C; Traves V; Quecedo E; Sanjuan-Gimenez J; Hemminki K; Landi MT; Kumar R
Int J Cancer; 2016 Jul; 139(1):75-84. PubMed ID: 26875008
[TBL] [Abstract][Full Text] [Related]
22. KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases.
Zebary A; Jangard M; Omholt K; Ragnarsson-Olding B; Hansson J
Br J Cancer; 2013 Aug; 109(3):559-64. PubMed ID: 23860532
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of BRAF and NRAS mutations in cutaneous melanoma patients in Taiwan.
Sheen YS; Liao YH; Liau JY; Lin MH; Hsieh YC; Jee SH; Chu CY
J Formos Med Assoc; 2016 Feb; 115(2):121-7. PubMed ID: 25767048
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
Yaman B; Akalin T; Kandiloğlu G
Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
[TBL] [Abstract][Full Text] [Related]
25. Heterogeneity of BRAF, NRAS, and TERT Promoter Mutational Status in Multiple Melanomas and Association with MC1R Genotype: Findings from Molecular and Immunohistochemical Analysis.
Pellegrini C; Di Nardo L; Cipolloni G; Martorelli C; De Padova M; Antonini A; Maturo MG; Del Regno L; Strafella S; Micantonio T; Leocata P; Peris K; Fargnoli MC
J Mol Diagn; 2018 Jan; 20(1):110-122. PubMed ID: 29061376
[TBL] [Abstract][Full Text] [Related]
26. A real-world study of adjuvant anti-PD -1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations.
Sun W; Xu Y; Yan W; Wang C; Hu T; Luo Z; Zhang X; Liu X; Chen Y
Cancer Med; 2023 Aug; 12(15):15945-15954. PubMed ID: 37403699
[TBL] [Abstract][Full Text] [Related]
27. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
[TBL] [Abstract][Full Text] [Related]
28. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
[TBL] [Abstract][Full Text] [Related]
29. Clinical, environmental and histological distribution of BRAF, NRAS and TERT promoter mutations among patients with cutaneous melanoma: a retrospective study of 563 patients.
Manrique-Silva E; Rachakonda S; Millán-Esteban D; García-Casado Z; Requena C; Través V; Kumar R; Nagore E
Br J Dermatol; 2021 Mar; 184(3):504-513. PubMed ID: 32506424
[TBL] [Abstract][Full Text] [Related]
30.
Bai X; Kong Y; Chi Z; Sheng X; Cui C; Wang X; Mao L; Tang B; Li S; Lian B; Yan X; Zhou L; Dai J; Guo J; Si L
Clin Cancer Res; 2017 Oct; 23(20):6120-6127. PubMed ID: 28720667
[No Abstract] [Full Text] [Related]
31. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
Griewank KG; Westekemper H; Murali R; Mach M; Schilling B; Wiesner T; Schimming T; Livingstone E; Sucker A; Grabellus F; Metz C; Süsskind D; Hillen U; Speicher MR; Woodman SE; Steuhl KP; Schadendorf D
Clin Cancer Res; 2013 Jun; 19(12):3143-52. PubMed ID: 23633454
[TBL] [Abstract][Full Text] [Related]
32. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Liu J; Liu Y
Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological characteristics and mutation profile of BRAF and NRAS mutation in cutaneous melanomas in the Western Turkish population.
Evrenos MK; Temiz P; Çam FS; Yaman M; Yoleri L; Ermertcan AT
Turk J Med Sci; 2018 Oct; 48(5):973-979. PubMed ID: 30384563
[TBL] [Abstract][Full Text] [Related]
34. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.
Mar VJ; Wong SQ; Li J; Scolyer RA; McLean C; Papenfuss AT; Tothill RW; Kakavand H; Mann GJ; Thompson JF; Behren A; Cebon JS; Wolfe R; Kelly JW; Dobrovic A; McArthur GA
Clin Cancer Res; 2013 Sep; 19(17):4589-98. PubMed ID: 23833303
[TBL] [Abstract][Full Text] [Related]
35. Melanoma.
Schadendorf D; Fisher DE; Garbe C; Gershenwald JE; Grob JJ; Halpern A; Herlyn M; Marchetti MA; McArthur G; Ribas A; Roesch A; Hauschild A
Nat Rev Dis Primers; 2015 Apr; 1():15003. PubMed ID: 27188223
[TBL] [Abstract][Full Text] [Related]
36. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
[TBL] [Abstract][Full Text] [Related]
37. BRAF, KIT, NRAS, GNAQ and GNA11 mutation analysis in cutaneous melanomas in Turkish population.
Yilmaz I; Gamsizkan M; Kucukodaci Z; Berber U; Demirel D; Haholu A; Narli G
Indian J Pathol Microbiol; 2015; 58(3):279-84. PubMed ID: 26275246
[TBL] [Abstract][Full Text] [Related]
38. Mutational Profile of Driver Genes in Brazilian Melanomas.
Vicente ALSA; Crovador CS; Macedo G; Scapulatempo-Neto C; Reis RM; Vazquez VL
J Glob Oncol; 2019 Nov; 5():1-14. PubMed ID: 31756131
[TBL] [Abstract][Full Text] [Related]
39. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
40. Genetic Alterations among Korean Melanoma Patients Showing Tumor Heterogeneity: A Comparison between Primary Tumors and Corresponding Metastatic Lesions.
Lee SH; Kim JE; Jang HS; Park KH; Oh BH; Shin SJ; Chung KY; Roh MR; Rha SY
Cancer Res Treat; 2018 Oct; 50(4):1378-1387. PubMed ID: 29361821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
